Zhi Xiang Shen

TL;DR: Data suggest bosutinib is effective and tolerable in patients with chronic phase imatinib-resistant or imatinIB-intolerant CML, and responses were seen across Bcr-Abl mutants, except T315I.

TL;DR: This prospective dataset confirms the efficacy and well characterizes the tolerability profile of deferasirox in a large population of patients with aplastic anemia and indicates that labile plasma iron levels were within normal range despite high serum ferritin levels.

TL;DR: Alongside reduction in iron overload, deferasirox may, therefore, improve hematologic parameters in a subset of aplastic anemia patients and further investigation is required to elucidate the mechanisms involved.

TL;DR: The results suggest that patients with suboptimal cytogenetic response are more likely to achieve improved cytogenetics with switching to nilotinib compared with imatinib dose escalation, and longer-term analyses are needed to establish whether the clinical benefits observed are associated with improved long-term survival outcomes.

TL;DR: To assess the efficacy and safety of deferasirox in Chinese thalassaemia major (TM) patients, a large number of patients will need to be enrolled for treatment with this drug.